CogCast is the Cogstate podcast series on measuring cognition in clinical trials.

Cognitive impairment and decline in cognitively normal older adults with high amyloid-b: A meta-analysis

June 1, 2017

The scientific community widely agrees that in cognitively normal older adults, abnormal levels of amyloid-beta, seen through PET imaging or CSF sampling, indicates that the pathophysiological process of Alzheimer’s disease has, in fact, begun; although it may still be decades before these individuals meet clinical criteria for dementia. Despite being cognitively normal, studies show that cognitive decline is faster and progression to Alzheimer’s disease is more rapid, in those individuals with higher levels of amyloid – and there’s a need to further characterize this early, preclinical stage of Alzheimer’s disease. Today’s podcast will discuss an important new publication from the journal, Alzheimer’s & Dementia, entitled “Cognitive impairment and decline in cognitively normal older adults with high amyloid: A meta-analysis”. Joining us are two of the study’s authors: Dr. Peter Snyder, Professor in the Department of Neurology at Warren Alpert Medical School of  Brown University, and Senior Vice President & Chief Research Officer at Lifespan Hospital System; and Dr. Paul Maruff, Professor at the Florey Institute for Neuroscience and Mental Health, and Chief Science Officer at Cogstate.

View the open access publication.